MULTIPLE SCLEROSIS THERAPEUTICS MARKET ANALYSIS

Key Developments

• In July 2024, Abata Therapeutics announced that the FDA had approved its Investigational New Drug (IND) application to begin a Phase 1 study of ABA-101 in patients with progressive multiple sclerosis (MS)
• In May 2024, iConquerMS People-Powered Research Network partnered with several institutions, including the VA and GAIA AG, for a four-year clinical trial to study digital therapeutics for treating fatigue in multiple sclerosis (MS). The trial is funded by US$ 4.5 million grant from the Department of Defense's Multiple Sclerosis Research Program.
• In March 2024, Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced the publication of a report, in Med1, describing the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in two patients suffering from progressive multiple sclerosis (MS) as part of a named patient program for critically ill patients after both patients failed to respond to conventional therapies
• In February 2024, Roche Pharma India announced the launch of Ocrevus for treating multiple sclerosis (MS) in India. Ocrevus, a leading product available in over 100 countries, is approved in India for both primary progressive and relapsing forms of multiple sclerosis, and aims to meet the needs of multiple sclerosis patients in the country.